{"id":16378,"date":"2026-06-18T23:43:33","date_gmt":"2026-06-18T20:43:33","guid":{"rendered":"https:\/\/nesiller.com\/multipl-miyelom-paneli\/"},"modified":"2026-10-26T14:13:22","modified_gmt":"2026-10-26T11:13:22","slug":"multiple-myeloma-panel","status":"publish","type":"page","link":"https:\/\/nesiller.com\/en\/oncology\/focus-hematology-panels\/multiple-myeloma-panel\/","title":{"rendered":"Multiple Myeloma Panel"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t
FOCUS Hematology Panels<\/a><\/div>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Multiple Myeloma Panel<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Multiple Myeloma is a type of blood cancer that develops when plasma cells, which are responsible for antibody production, proliferate uncontrollably in the bone marrow. The accumulation of abnormal plasma cells can disrupt normal blood cell production and lead to complications such as bone damage, anemia, and impaired kidney function. Various genetic and chromosomal abnormalities may contribute to the development of Multiple Myeloma; however, the exact cause of the disease is not fully understood in most cases.<\/p>

Treatment for Multiple Myeloma depends on the stage of the disease, the patient’s overall health, and disease-specific characteristics. Treatment options may include targeted therapies, immunomodulatory drugs, corticosteroids, chemotherapy, and autologous stem cell transplantation in eligible patients. Genetic and chromosomal analyses can contribute to understanding the biological characteristics of the disease and support clinical decision-making in treatment planning.<\/p>
Genetic Alterations<\/strong><\/td>Method<\/strong><\/td>Sample Type<\/strong><\/td><\/tr>
5q31 Deletion<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr>
7q31 Deletion<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr>
20q12 Deletion<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr>
Trisomy \/ Monosomy 7<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr>
Trisomy \/ Monosomy 8<\/td>FISH<\/td>Bone Marrow \/ Heparinized Blood<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

FOCUS Multiple Myeloma Panel analyzes 5q31, 7q31 and 20q12 deletions and trisomy\/monosomy of chromosomes 7 and 8 by FISH in bone marrow or heparinized blood.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":16386,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-16378","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/16378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/comments?post=16378"}],"version-history":[{"count":19,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/16378\/revisions"}],"predecessor-version":[{"id":22028,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/16378\/revisions\/22028"}],"up":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/16386"}],"wp:attachment":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/media?parent=16378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}